Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTAA91 in refractory rheumatoid arthritis
NCT06982547Phase 1Not yet recruiting
- Sponsor
- PersonGen BioTherapeutics
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of UTAA91 in rheumatoid arthritis (RA), sponsored by PersonGen BioTherapeutics. Primary endpoint: Adverse events at 1 year. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
UTAA91
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06982547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06982547.